The Cigna Group (CI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Annual meeting scheduled for April 22, 2026, with voting available online or virtually at the meeting.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of 12 directors, each recommended by the board for approval.
Advisory vote on executive compensation, with board recommending approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026, recommended by the board.
Shareholder proposal on the right to act by written consent, with board recommending a vote against.
Record date for voting eligibility set as February 23, 2026.
Board of directors and corporate governance
Nominees for director include individuals with diverse backgrounds and expertise.
Board provides recommendations for each director nominee and all voting items.
Latest events from The Cigna Group
- Strong 2025 results, portfolio focus, and leadership transition headline this year’s proxy.CI
Proxy Filing13 Mar 2026 - Rebate-free PBM model and specialty pharmacy expansion drive growth and transparency.CI
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2025 revenue up 11% to $275B; 2026 EPS guidance at least $30.25, FTC settlement resolved.CI
Q4 20255 Feb 2026 - Q2 revenue up 25%, adjusted EPS up 10%, and $3.7B Medicare sale expected in Q1 2025.CI
Q2 20242 Feb 2026 - EPS guidance reaffirmed, share repurchases prioritized, and specialty pharmacy drives growth.CI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Growth in specialty, pharmacy, and benefits segments drives innovation and strong financial outlook.CI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Specialty drug growth and biosimilars drive market leadership and significant client savings.CI
Bernstein Healthcare 1:1 Forum 202420 Jan 2026 - Q3 2024 revenue up 30% to $63.7B, EPS up 11%, but net income down on VillageMD loss.CI
Q3 202417 Jan 2026 - 2024 revenue up 27% to $247.1B; 2025 EPS guidance at $29.50 with strong capital returns.CI
Q4 20249 Jan 2026